Skip to main content
Quest Diagnostics

Identifying Ashkenazi Jewish Founder Variants in Combination With a Second Significant Finding

ACMG Annual Clinical Genetics Meeting, 2024

American College of Medical Genetics and Genomics

Toronto, Canada, March 12-16, 2024

Poster presentation: Identifying Ashkenazi Jewish Founder Variants in Combination With a Second Significant Finding

Authors: Basiliere MS, Nordquist EN, Weltmer EC

Specialty: Genetics, Oncology

Related content

On-Demand Webinar
Hereditary Cancer Care Starts in Primary Care
Publication
Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study
Test FAQ
BRCA Ashkenazi Jewish Screen
Test FAQ
BRCA Ashkenazi Jewish Screen with Reflex to BRCA Panel BRCA1 BRCA2
Conference Presentation
Detection of Germline and Somatic BRCA Mutations Using a 50 Gene Next Generation Sequencing Panel

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.